DNTH103

Phase 3Small molecule

DNTH103 is one of 98 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Myasthenia GravisActive, not recruiting

NeuropathyActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Active, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

NeuropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Savella

AbbVie

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Vimpat

UCB

Phase 3

1 4

Asceniv

CSL Behring

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Claritin

PPerrigo Company

Phase 3

1 7

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Myasthenia Gravis

NCT06282159

Q1 2028

Phase 2Recruiting

Neuropathy

NCT06537999

Q4 2030

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyneuropathy

NCT06858579

Clinical

Trials by Indication[1]

Myasthenia Gravis1 trial

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Active, not recruiting·DDianthus Therapeutics·Phase 2·NCT06282159·65 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Recruiting·DDianthus Therapeutics·Phase 3·NCT06858579·256 enrolled

Neuropathy1 trial

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)

Recruiting·DDianthus Therapeutics·Phase 2·NCT06537999·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for DNTH103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DNTH103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DNTH103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dianthus Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDianthus Therapeutics

DNTH103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Q4 2030

Trials by Indication[1]

Myasthenia Gravis1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Neuropathy1 trial

References

Drug Info

Quick Facts

Related News